QUOTE AND NEWS
TheStreet.com  Apr 11  Comment 
NEW YORK (TheStreet) -- MannKind  continued its decline Friday after news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin...
SeekingAlpha  Apr 11  Comment 
ByScrying Biotech: It was like something out of a George Lucas episode of Star Wars. The Empire had summoned a quorum to discuss the future of mankind. The directives of that meeting were released near evening the day before it was to take place....
TheStreet.com  Apr 10  Comment 
NEW YORK (TheStreet) -- MannKind  dipped Thursday amid news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own...
SeekingAlpha  Apr 10  Comment 
By Think Long Term: By now, investors across the world have heard about the recent FDA advisory panel overwhelmingly recommending approval of Afrezza in astounding fashion for both type 1 and type 2 diabetes for MannKind (MNKD). Investors know...
Benzinga  Apr 8  Comment 
In a note released Tuesday, Brinson Patrick Initiated coverage on MannKind (NASDAQ: MNKD) at Market Outperform and announced a $12 price target. Brinson Patrick analyst Christopher James emphasized the expected FDA approval of the diabetes drug...
SeekingAlpha  Apr 8  Comment 
BySharon di Stefano: A recent FDA panel recommended for approval an inhalable form of insulin made by MannKind Corp. (MNKD) for both Type 1 and Type 2 diabetes amid strong votes from an outside team of experts, almost ensuring final marketing...
newratings.com  Apr 8  Comment 
FOSTER CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) has submitted new drug applications with FDA for its investigational products Daclatasvir and Asunaprevir seeking approval for their combined use in patients with genotype 1b hepatitis C. The...
SeekingAlpha  Apr 7  Comment 
By George Rho: On April 1, 2014, the Endocrinologic and Metabolic Drugs Advisory Committee ((AdCom)) convened to discuss and vote on whether to recommend the Food & Drug Administration approve MannKind Corporation's (NASDAQ: MNKD) New Drug...
SeekingAlpha  Apr 7  Comment 
ByQuoth the Raven: Shorts proved me wrong on MannKind (MNKD) last week. I contended that after the company's positive 13-1 vote at ADCOM that the shorts could continue to squeeze the stock through its highs in the upper $8 region to end the week....
SeekingAlpha  Apr 7  Comment 
By Tri Duong: In my previous article about MannKind (MNKD) Afrezza probability of Food & Drug Administration Approval, there were many constructive criticisms regarding Advisory Committee results that I want to address. Before I do that, I want to...




 

MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.

Competition

MannKind's primary competitors include:

References

  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki